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ABSTRACT
The genes encoding 14-sterol demethylases (cyp51A and cyp51B) were analysed in twelve
ITC-resistant and three ITC-susceptible clinical isolates of Aspergillus fumigatus. Six ITC-
resistant strains exhibited a substitution of glycine 54 per another amino acid, located at a very
conserved region of the Cyp51A protein. The cyp51A gene from the A. fumigatus wild type (CM-
237) strain was replaced for the mutated cyp51A gene copy of one ITC-resistant strain (AF-72).
Two transformants exhibited resistance to itraconazole and both had incorporated the cyp51A
gene mutated copy.
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Aspergillus infections are an important cause of mortality and morbidity in the
immunocompromised host, and Aspergillus fumigatus is one of the most prevalent airborne
fungal pathogens causing infection worldwide (13). A. fumigatus is intrinsically resistant to
fluconazole, unlike itraconazole, which has been shown to have good in vitro and in vivo activity
against this species (3). However, a number of A. fumigatus isolates with in vitro itraconazole
resistance have been described (1, 6, 9). In some instances, the resistance detected in vitro has
been confirmed in vivo with animal models (5, 10).
The azole-derived antifungal agents inhibit the ergosterol biosynthesis pathway via the inhibition
of 14-demethylase, the enzyme that removes the methyl group at position C-14 of precursor
sterols. The emergence of resistance to azoles in yeast has accelerated studies of the
mechanisms implicated in this resistance, and several alterations of the gene encoding the 14-
demethylase (ERG11/cyp51) had been reported in fluconazole-resistant clinical isolates of
Candida albicans (12, 14, 16, 21, 24). The mechanisms of resistance to azoles have been
studied at some extent for phytopathogenic fungi, but the information about human pathogenic
filamentous fungi is very meager. The occurrence of a phenylalanine residue at the position 136
of the cyp51 sequence instead of a tyrosine residue has been reported for field isolates of
Uncinula necator (8) and Erysiphe graminis (7). In these fungi the Y136F mutation is related to
resistance to demethylation inhibitors (DMIs). To date, two molecular mechanisms of resistance
to itraconazole has been proposed in A. fumigatus: one is the reduced intracellular
accumulation of itraconazole, due to an efflux pump (9, 25) and also, a reduced penetration of
the drug has been suggested (15). The other one is related to a possible modification of the
target enzyme 14-sterol demethylase or its overexpression (9, 20).
Recently, we have described the existence of two genes coding two different 14-demethylases
in A. fumigatus, cyp51A and cyp51B. Also, it has been shown that both genes are expressed
(17). The cyp51A sequence did exactly match with one previously described sequence of A.
fumigatus (11). The objective of this work was to compare the sequences of these two genes in
itraconazole-susceptible and itraconazole-resistant isolates of A. fumigatus looking for specific
residues that could account, at least in part, for the resistance of A. fumigatus to itraconazole.
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A total of fifteen clinical strains of A. fumigatus were selected on the basis of their
susceptibilities to itraconazole (ITC): i) resistant isolates (R) AF-72, AF-90, AF-91, AF-1422,
F/6929, F/7075, Br130, Br181, AF-1237, CM-796, CM1910 and SO/3829 had minimal inhibitory
concentrations (MICs) to ITC  8.0 µg/ml (4, 9, 18). ii) susceptible isolates (S) AF-1119, CM-
1369, CM-237 had ITC MICs of 0.5 µg/ml. AF-1119 was isolated four months before AF-1237
and before itraconazole treatment (4). Isolates CM-1369 and CM-796 were obtained from two
BAL samples, separated eleven months, from one HIV-positive patient. Strain CM-1910 was
obtained from the sputum of a patient. A. fumigatus CM-237 was used as control strain. This
isolate was utilized for describing the sequence of the genes cyp51A and cyp51B (17).
Paecilomyces variotii ATCC22319 and A. fumigatus ATCC9197 were used as quality control
strains for susceptibility testing.
Antifungal susceptibility testing. Despite most of the strains had been previously checked for
ITC susceptibility, antifungal susceptibility testing was repeated. A broth microdilution test was
performed by following the NCCLS reference method (19), with minor modifications (3).
Itraconazole (ITC) (Janssen Pharmaceutica, Madrid, Spain), voriconazole (VCZ) (Pfizer S.A.,
Madrid, Spain), fluconazole (FCZ) (Pfizer S.A., Madrid, Spain), and ketoconazole (KTZ)
(Janssen Pharmaceutica, Madrid, Spain) were obtained as standard powder from their
respective manufacturers. Drugs were dissolved in dimethyl sulfoxide (DMSO) (Sigma, Madrid,
Spain) to obtain stock solutions of 1600 µg/ml that were conserved at –70ºC. For ITC, VCZ and
KTZ the final concentration range assayed was 8.0-0.015 µg/ml. FCZ was assayed using
concentration ranges from 6,400-0.03 µg/ml. Visual readings were performed with a microtiter
reading mirror. MICs were defined as the lowest concentration of the antifungal agent that
completely inhibits fungal growth at 48 hours of incubation at 35ºC. Susceptibility tests were
performed at least twice with each strain at different days.
Three isolates, CM-1369, AF-1119 and CM-237 had ITC MICs of  0.5 µg/ml. The rest of the
isolates was confirmed to be resistant in vitro to ITC, with MICs values  8.0 µg/ml (Table 1).
Although there are no defined breakpoints for ITC, we considered that those isolates with ITC
MICs  0.5 µg/ml were susceptible and the strains with ITC MICs  8.0 µg/ml were resistant.
This putative breakpoints were chosen on the basis of previous works that correlated an ITC
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MIC of higher than 8 µg/ml with the lack of clinical response to the treatment with ITC and the
lack of response in animal models (5, 10). MICs values for other azole drugs are shown in
Table 1.
PCR-amplification and sequencing of A. fumigatus cyp51A and cyp51B genes Conidia
from each strain were inoculated into 3 ml GYEP broth (2% glucose, 0.3% yeast extract, 1%
peptone) and they were grown overnight at 37ºC. Mycelia mats were recovered and subject to a
DNA extraction protocol described previously (26). The full coding sequences of cyp51A and
cyp51B were amplified by using specific primer sets: P450-A1 (5´-ATGGTGCCGATGCTATGG-
3´) and P450-A2 (5´-CTGTC-TCACTTGGATGTG-3´) for the cyp51A gene and P450-B1 (5´-
ATGGGTCTCATCGCGTTC-3´) and P450-B2 (5´-TCAGGCTTTGGTAGCGG-3´) for the gene
cyp51B. The amplifications were performed in a 50 µl volume as previously described (17).
Negative controls including all PCR constituents but without DNA were included in each
amplification run. The PCR products were analyzed by electrophoresis on agarose gels and
stained with ethidium bromide. Sequence analysis of cyp51A and cyp51B genes showed some
point mutations. To verify that these point mutations were not due to errors in the PCR
amplification of the genes, the two genes cyp51A and cyp51B from all isolates were newly
amplified and sequenced a second time. Exactly the same point mutations were found again,
indicating that they were not artificially introduced during the PCR.
The target of the azole antifungals is the 14-demethylase, and alterations in the sequence of
the gene encoding this enzyme (ERG11/cyp51) has been demonstrated in C. albicans resistant
to azoles (12, 14, 16, 21, 24) and in some phytopatogenic fungi resistant to DMIs (7, 8). Thus, in
this work, alteration of the cyp51 genes of A. fumigatus is proposed as one of several potential
mechanisms for resistance to ITC. The detection of amino acids substitutions in the Cyp51A
and/or Cyp51B proteins of those isolates with phenotypic resistance to ITC when compared with
the same proteins of ITC-susceptible strains would allow to associate the specific alteration with
resistance to ITC. PCR amplification and sequence analysis of cyp51A genes showed some
point mutations: six ITC-resistant strains presented a single base change (CM-796, AF-72, AF-
1237, F/7075, Br130 and Br181) (Table 1). These single base mutations lead to changes at
triplet encoding amino acid 54 (glycine). This residue is located at a very conserved region of
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the Cyp51 proteins. These mutations were the change of G to T at position 161 (g161t) (in CM-
796, and Br181 strains), the change of g161a (in AF-72, F/7075 and Br130 strains) and g160a
in the AF-1237 strain. In addition, five other strains (AF-90, AF-1, AF-1422, F/6929 and
SO/3829) showed a different mutation which yielded an amino acid substitution of methionine
(M) to valine (V), lysine (K) or threonine (T) at codon 236 (Table 1). This methionine 236 is not a
conserved amino acid between different yeast and moulds Cyp51s. Regarding cyp51B gene,
five additional point mutations were observed in the cyp51B sequence of some of the ITC-
resistant strains (Table 1). Only two of these changes lead to amino acid substitutions: in AF-72
and Br130 strains the a125t change lead to amino acid substitution of glutamine (Q) to leucine
(L) at codon 42. (these two strains harboured another mutation c664t which is not responsible
for an amino acid substitution). One strain (SO/3829) had a t1264a change at codon 387 that
would be responsible for aspartic acid (D) to glutamic acid (E) substitution. Three ITC-resistant
isolates, Br-181, F/6919 and AF-1237, did not show any change in their sequence of cyp51B
gene with respect to the reference strain CM-237. The strains CM-796, AF-90, AF-91, CM-1910
and AF-1422 showed a base change at the position 105 (t105c) in the cyp51B sequences when
compared to the reference stain (CM-237), but this change was not associated with an amino
acid alteration. In total, four different point mutations were detected among twelve ITC-resistant
isolates that yield amino acid substitutions. The strain AF-1237, which harboured the amino acid
substitution G54R at Cyp51A, it was matched with the initially ITC-susceptible strain AF-1119.
Both were obtained from the same patient and they were shown to have identical DNA patterns
by different molecular typing methods (4). These two strains only differed in the amino acid at
the position 54 of Cyp51A sequence. These findings demonstrate that the mutation at glycine
54 is responsible, at least in part, of the ITC-resistance of strain AF-1237. The fact that another
five ITC-resistant strains, harbored a mutation at the same position of Cyp51A suggests that
there is a high correlation of this specific substitution with resistance to ITC. In addition,
fragments containing the area with the mutation (160/161 position) were PCR amplified (using
primer A7 and A5, see below) and sequenced from 22 A. fumigatus ITC- susceptible strains
from our mould collection of clinical strains. All A. fumigatus ITC-S strains have the triplet ggg at
160-162 position (G54).
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Regarding the other two mutations resulting in amino acid substitution, previous work, has
suggested an altered membrane transporter to be the mechanism of resistance operating in the
strain AF-72, as a reduced intracellular concentration of azoles was found in this strain (9).
Strain AF-72 harbored one mutation in each of the two 14-sterol demethylases, the
substitutions G54E in Cyp51A and Q42L in Cyp51B. The mutation Q42L detected in this strain
was only present in another resistant strain. This fact together with a G54E mutation from AF-72
resulting in ITC-resistance in the wild type CM-237 recipient strain (which does not bear the
Q42L mutation), suggests that there is not a direct involvement in of that amino acid change
(Q42L) in the resistance of A. fumigatus to ITC. On the other hand, the resistance to ITC of
strains AF-90 and AF-91 was previously reported to be mediated by either increased expression
of the 14-sterol demethylase, or altered enzyme affinity for azoles (9). Both strains were from
the same patient and they are resistant to ITC. We found the mutation a729t leading to M236V
substitution in a variable region of the Cyp51A of strains: AF-91, AF-90, AF1422, F/6919 and
SO/3829. Moreover, M236V and Q42L substitutions are both situated in protein areas which are
not conserved in other Cyp51 enzymes. It seems therefore unlikely that neither M236V, nor
Q42L would be related to A. fumigatus itraconazole resistance. Nevertheless, the appearance
of M236 substitution in five strains with similar pattern of azole drugs resistance deserves
consideration. Sequencing of Cyp51A and Cyp51B genes of more ITC-resistant strains is
needed before further conclusions can be drawn.
Replacement of the 237 wild type cyp51A gene for the mutated AF-72 cyp51A gene copy
by DNA-mediated transformation using electroporation. The cyp51A gene from AF-72
strain was PCR amplified as previously described and introduced into the 237 wild type strain.
Transformations of A. fumigatus 237 strain was achieved by electroporation using a protocol
previously described for A. nidulans (23) and that it was adapted for A. fumigatus (27). In the
last step the protocol was slightly modified as follows: After electroporation and incubation at
30ºC for 90 min on a rotary shaker, transformation mixtures were cultured on 20 ml minimal
medium (2) agar plates containing 1% glucose and 5mM ammonium tartrate and incubated
overnight at room temperature. The day after, 10 ml of melted minimal medium (0.6 % agarose)
containing 200 g of ITC, were poured plated over the medium to make a final concentration of
8
8 g/ml. The plates were incubated at 37ºC for a week. Itraconazole resistant transformants
were appearing at variable times ranging from 2–7 days. Mutants were named by a letter (T)
followed by a number. DNA from ITC-resistant transformants were digested with two different
restriction enzymes (SalI and EcoRI) (Amersham-Pharmacia Biothech, Madrid, Spain) and
fractionated by electrophoresis through 0.8% agarose gels in TAE buffer and subjected to
Southern blot analysis using a fragment of cyp51A gene as a probe (17, 22).
The cyp51A gene from AF-72 strain was introduced into the 237 wild type strain by
electroporation. After 48 hours of incubation two transformant strains (T-21 and T-23) resistant
to itraconazole were obtained. Both transformants had only one copy of the cyp51A gene (as
shown by the fact that only a single hybridization band appeared after digestions with two
different restriction enzymes) (results not shown). In order to ensure that no errors occurred
during gene replacement (such a DNA deletions or insertions that could have affected cyp51A
gene transcription), PCR amplification of the 5´ and 3´ cyp51A ends from both ITC-resistant
transformants was used. Two primer sets (A7 + A5, and A9 + A6), previously described (17)
were used to PCR amplify DNA fragments of 600 bp and 500 bp respectively. Those fragments
included the non coding sequences surrounding the 5´ and 3´ cyp51A ends. The ITC resistance
(MIC > 8.0 g/ml) of T-21 and T-23 was confirmed by the microdilution method (3, 19). MICs for
the rest of azole drugs showed similar pattern that of the six strains carrying the G54
substitution (Table 1). PCR amplification of cyp51A and cyp51B genes from these two
transformants and full sequencing of the genes confirmed that both of them have incorporated
the cyp51A gene mutated copy (g161a change leading to a glycine/glutamic acid substitution at
codon 54). None of the mutants have any other base change present in either the rest of the
cyp51A gene or in the cyp51B gene.
The replacement of the cyp51A gene from A. fumigatus wild type (CM-237) strain with the
mutated cyp51A gene of AF-72, changed the susceptibility pattern of CM-237 to ITC-resistant.
Because we have used a direct itraconazole resistance selection for identifying the gene
replacement event incorporating the mutation, we can not rule out the possibility of an
spontaneous mutation by drug selective pressure. Although, two facts should be consider: (i) no
transformants ITC-resistant were obtained when the wild type spores were electroporated using
distilled water without DNA, ruling out in part the possibility of an spontaneous mutation and (ii)
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the six strains with G54 substitution harboured three different base changes (gag, gtg, or agg)
so that, the existence of two independent transformants harbouring exactly the same mutated
54 codon (gag) will speak in favour of the gene replacement event incorporating the cyp51A
mutated copy of AF-72. In conclusion, results strongly suggest that a point mutation leading to
G54 substitution for other amino acids is related to A. fumigatus ITC-resistance.
It is noteworthy that all strains (but CM-796) carrying the G54 substitution presented a 4X
decrease of the MICs of FCZ and KTC while they have no change in MICs of VCZ (Table 1).
Also mutants T-21 and T-23 had similar susceptibility patterns. Contrarily, the other six strains
presented MICs > 1600g/ml (at least 2.5 X increase) of FCZ and a moderate elevation for VCZ
and KTZ MICs (Table 1). In ITC resistant strains it seems remarkable the 20 X fluctuation of
MICs for FCZ between strains with or without the G54 substitution. Whatever the nature of the
change due to the G54 substitution, it seems to produce a better molecular environment for
FCZ and KCZ access and/or interaction. Strain CM-796 exhibited no variation in its
susceptibility against the three antifungal tested. However, coexistence of different mechanism
of resistant can not currently be discarded. At least two different azole susceptibility patterns
has been already described for some of these strains (18). The results presented here could
match one of these patterns with the G54 substitution.
The surveillance of ITC-resistant strains of A. fumigatus and the study of the resistance
mechanisms operating in them could help to understand the mechanisms of drug resistance
and to develop newer and more active molecules. Further investigations on the functional
analysis of the Cyp51A and Cyp51B proteins of A. fumigatus are straight forward.
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